Lee Dong Hoon, Kim Yoon Jeon, Yoon Young Hee
Department of Ophthalmology, The Eagle Eye Clinic, Seongnam, South Korea.
Ophthalmologica. 2016;235(3):150-6. doi: 10.1159/000443751. Epub 2016 Feb 24.
To evaluate the 1-year results of 25-gauge microincision vitrectomy surgery (MIVS25) combined with intraoperative dexamethasone (DEX) implant for persistent diabetic macular edema (DME).
This study enrolled patients who had a history of DME for ≥12 months and underwent MIVS25 and DEX implant injection. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were assessed postoperatively.
Eighteen eyes were included in the analysis. Preoperatively, logMAR BCVA was 0.90 and CRT was 594 µm on average. CRT decreased until the 3-month follow-up visit and tended to increase at 6 months, but stabilized at 12 months with additional treatments in five eyes at 5 months postoperatively. Statistically significant improvement in BCVA was noted 1 month after treatment and at each subsequent follow-up visit (p < 0.001).
MIVS25 combined with DEX implant injection might be utilized as an effective and safe alternative treatment for intractable DME.
评估25G微切口玻璃体切除术（MIVS25）联合术中地塞米松（DEX）植入治疗持续性糖尿病性黄斑水肿（DME）的1年效果。
本研究纳入有DME病史≥12个月且接受MIVS25和DEX植入注射的患者。术后评估最佳矫正视力（BCVA）和中心视网膜厚度（CRT）。
18只眼纳入分析。术前，logMAR BCVA平均为0.90，CRT平均为594µm。CRT在3个月随访时下降，6个月时趋于增加，但在12个月时稳定，5只眼在术后5个月进行了额外治疗。治疗后1个月及随后各次随访时BCVA均有统计学意义的改善（p<0.001）。
MIVS25联合DEX植入注射可作为难治性DME的一种有效且安全的替代治疗方法。
